AntriaBio announces successful tests for AB101 once-weekly basal insulin diabetes treatment

AntriaBio announces successful tests for AB101 once-weekly basal insulin diabetes treatment

LOUISVILLE - AntriaBio Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended-release therapies, announced it has successfully completed a series of in-vitro... Read More

By: InnovatioNews Thursday January 8, 2015 0 comments Tags: AB101, AntriaBio, Brian Roberts, C. Ronald Kahn, diabetes, Louisville